SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

The TSX parent reported adjusted earnings per share of 48 cents, topping the Street’s expectation by 4 cents as organic ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

The US government has placed an order with Merck & Co to buy ... of Gilead Sciences' antiviral Veklury (remdesivir) as the pandemic gathered pace last year, That drug has proved to be a mainstay ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus ...

Merck is one of the world’s largest ... Its leading drugs include HIV drugs Biktarvy and Genvoya and antiviral medication Veklury. Hellweg says Gilead is a market leader in HIV and oncology ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...